NYSE:NVTA Invitae (NVTA) Stock Price, News & Analysis → Controversial CEO explains new way to amass wealth (From Stansberry Research) (Ad) Free NVTA Stock Alerts $0.0035 0.00 (0.00%) (As of 05/3/2024) Add Compare Share Share Today's Range$0.0007▼$0.003550-Day Range$0.00▼$0.0252-Week Range$0.02▼$0.02Volume187,761 shsAverage Volume23.72 million shsMarket Capitalization$934,535.00P/E RatioN/ADividend YieldN/APrice Target$1.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Invitae alerts: Email Address Invitae MarketRank™ Stock AnalysisAnalyst RatingStrong Sell1.00 Rating ScoreUpside/Downside28,471.4% Upside$1.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.05) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.93 out of 5 stars 2.5 Analyst's Opinion Consensus RatingInvitae has received a consensus rating of Strong Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 3 sell ratings.Amount of Analyst CoverageInvitae has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NVTA. Previous Next 0.0 Dividend Strength Dividend YieldInvitae does not currently pay a dividend.Dividend GrowthInvitae does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInvitae has received a 71.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private genetic testing services" and "Diagnostic test kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Invitae is -1.13. Previous Next 1.2 News and Social Media Coverage News SentimentInvitae has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Invitae this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 4 people have added Invitae to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invitae insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.74% of the stock of Invitae is held by insiders.Percentage Held by Institutions61.28% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Invitae are expected to grow in the coming year, from ($1.05) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvitae has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About Invitae Stock (NYSE:NVTA)Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Read More NVTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVTA Stock News HeadlinesMay 1, 2024 | americanbankingnews.comInvitae (NYSE:NVTA) Receives New Coverage from Analysts at StockNews.comApril 28, 2024 | msn.comLabcorp to acquire Invitae in strategic dealMay 7, 2024 | InvestorPlace (Ad)The 2024 crypto bull run has already started — don’t get left behindOne of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.April 26, 2024 | uk.investing.comLabcorp to acquire Invitae assets for $239 millionApril 26, 2024 | bizjournals.comLabcorp wins $239M bid for bankrupt InvitaeApril 25, 2024 | msn.comLabcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae DealApril 25, 2024 | finanznachrichten.deInvitae Corporation: Invitae Enters into Agreement with Labcorp for Sale of BusinessApril 25, 2024 | marketwatch.comLabcorp to Buy Assets of Bankrupt Invitae for $239MMay 7, 2024 | InvestorPlace (Ad)The 2024 crypto bull run has already started — don’t get left behindOne of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.April 24, 2024 | reuters.comClinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mlnApril 24, 2024 | finance.yahoo.comInvitae Enters into Agreement with Labcorp for Sale of BusinessApril 24, 2024 | prnewswire.comLabcorp Announces Winning Bid for Select Assets of InvitaeApril 22, 2024 | tmcnet.comInvitae Publishes its Environmental, Social and Governance (ESG) ReportApril 11, 2024 | finance.yahoo.comInvitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain SignificanceApril 11, 2024 | prnewswire.comInvitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain SignificanceApril 2, 2024 | bizjournals.comPioneering cancer test company wants court to slow potential sale of Invitae's cancer-monitoring productsMarch 12, 2024 | finance.yahoo.comInvitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant ClassificationMarch 11, 2024 | reuters.comNVTA.PKMarch 9, 2024 | reuters.comNVTA.NMarch 6, 2024 | finanznachrichten.deInvitae Corporation: Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | prnewswire.comInvitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial ResultsMarch 5, 2024 | prnewswire.comInvitae to Present Data at the 2024 ACMG Annual Clinical Genetics MeetingMarch 3, 2024 | finance.yahoo.comNVTA Jun 2024 0.500 putFebruary 26, 2024 | finance.yahoo.comNVTA Jan 2026 1.500 callFebruary 17, 2024 | finance.yahoo.comNVTA Mar 2024 0.500 putFebruary 15, 2024 | msn.comInvitae gets court approval for five-month bankruptcy saleFebruary 15, 2024 | bizjournals.comGenetic testing pioneer Invitae files for bankruptcy protectionSee More Headlines Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNYSE:NVTA CUSIPN/A CIK1501134 Webwww.invitae.com Phone(628) 213-3369FaxN/AEmployees1,700Year FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.50 Low Stock Price Target$0.50 Potential Upside/Downside+28,471.4%Consensus RatingStrong Sell Rating Score (0-4)1.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,106,290,000.00 Net Margins-299.14% Pretax Margin-301.93% Return on Equity-6,100.71% Return on Assets-19.68% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.25 Sales & Book Value Annual Sales$481.58 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book0.01Miscellaneous Outstanding Shares267,010,000Free Float284,373,000Market Cap$934,535.00 OptionableOptionable Beta1.59 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Randal W. Scott Ph.D. (Age 66)Co-Founder & Chairman of the Board Comp: $50kMr. Kenneth D. Knight (Age 63)President, CEO & Director Comp: $1.4MMr. Thomas R. Brida (Age 53)General Counsel, Chief Compliance Officer & Secretary Comp: $776.72kMs. Ana J. Schrank (Age 58)Chief Accounting Officer & CFO Dr. David B. Sholehvar M.D. (Age 56)Chief Operating Officer Ms. Hoki Luk (Age 48)Head of Investor Relations and Capital Markets Ms. Shelly D. Guyer (Age 64)Chief Sustainability Officer Comp: $430.44kMs. Desarie FrenchChief Talent OfficerDr. W. Michael Korn M.D.Chief Medical OfficerMr. Robert GuigleyChief Commercial OfficerMore ExecutivesKey CompetitorsAmpio PharmaceuticalsNYSE:AMPEAptevo TherapeuticsNASDAQ:APVOAthersysNASDAQ:ATHXPeak BioNASDAQ:PKBOSmart for LifeNASDAQ:SMFLView All CompetitorsInsiders & InstitutionsVestmark Advisory Solutions Inc.Bought 839,007 shares on 2/6/2024Ownership: 0.293%Robert L NussbaumSold 7,086 sharesTotal: $9,778.68 ($1.38/share)Kenneth D KnightSold 45,432 sharesTotal: $54,518.40 ($1.20/share)Yafei WenSold 43,452 sharesTotal: $86,469.48 ($1.99/share)Robert L NussbaumSold 26,476 sharesTotal: $31,771.20 ($1.20/share)View All Insider TransactionsView All Institutional Transactions NVTA Stock Analysis - Frequently Asked Questions Should I buy or sell Invitae stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 3 sell ratings for the stock. The consensus among Wall Street analysts is that investors should "strong sell" NVTA shares. View NVTA analyst ratings or view top-rated stocks. What is Invitae's stock price target for 2024? 3 equities research analysts have issued twelve-month price targets for Invitae's stock. Their NVTA share price targets range from $0.50 to $1.50. On average, they predict the company's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 28,471.4% from the stock's current price. View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts. How have NVTA shares performed in 2024? Invitae's stock was trading at $0.6268 at the beginning of the year. Since then, NVTA stock has decreased by 99.4% and is now trading at $0.0035. View the best growth stocks for 2024 here. How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) issued its quarterly earnings data on Tuesday, May, 9th. The medical research company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.04. The medical research company earned $117.36 million during the quarter, compared to the consensus estimate of $116.57 million. Invitae had a negative net margin of 299.14% and a negative trailing twelve-month return on equity of 6,100.71%. The company's revenue was down 5.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.78) earnings per share. What is Sean George's approval rating as Invitae's CEO? 59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA). When did Invitae IPO? Invitae (NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. How do I buy shares of Invitae? Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NVTA) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersNo experience to confident trader, meet my student…Wealth Builders InstituteBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
